These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 11007134)
1. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Tran A; Benzaken S; Saint-Paul MC; Guzman-Granier E; Hastier P; Pradier C; Barjoan EM; Demuth N; Longo F; Rampal P Eur J Gastroenterol Hepatol; 2000 Sep; 12(9):989-93. PubMed ID: 11007134 [TBL] [Abstract][Full Text] [Related]
2. Plasma YKL-40: a new potential marker of fibrosis in patients with alcoholic cirrhosis? Johansen JS; Møller S; Price PA; Bendtsen F; Junge J; Garbarsch C; Henriksen JH Scand J Gastroenterol; 1997 Jun; 32(6):582-90. PubMed ID: 9200292 [TBL] [Abstract][Full Text] [Related]
3. Serum YKL-40 is increased in patients with hepatic fibrosis. Johansen JS; Christoffersen P; Møller S; Price PA; Henriksen JH; Garbarsch C; Bendtsen F J Hepatol; 2000 Jun; 32(6):911-20. PubMed ID: 10898311 [TBL] [Abstract][Full Text] [Related]
4. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. Saitou Y; Shiraki K; Yamanaka Y; Yamaguchi Y; Kawakita T; Yamamoto N; Sugimoto K; Murata K; Nakano T World J Gastroenterol; 2005 Jan; 11(4):476-81. PubMed ID: 15641129 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Mehta P; Ploutz-Snyder R; Nandi J; Rawlins SR; Sanderson SO; Levine RA Am J Gastroenterol; 2008 Apr; 103(4):928-36. PubMed ID: 18371145 [TBL] [Abstract][Full Text] [Related]
6. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Vind I; Johansen JS; Price PA; Munkholm P Scand J Gastroenterol; 2003 Jun; 38(6):599-605. PubMed ID: 12825867 [TBL] [Abstract][Full Text] [Related]
7. Serum levels of YKL-40 and PIIINP as prognostic markers in patients with alcoholic liver disease. Nøjgaard C; Johansen JS; Christensen E; Skovgaard LT; Price PA; Becker U; J Hepatol; 2003 Aug; 39(2):179-86. PubMed ID: 12873813 [TBL] [Abstract][Full Text] [Related]
8. Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection. Schiavon LL; Narciso-Schiavon JL; Carvalho Filho RJ; Sampaio JP; Medina-Pestana JO; Lanzoni VP; Silva AE; Ferraz ML J Viral Hepat; 2008 Sep; 15(9):666-74. PubMed ID: 18482283 [TBL] [Abstract][Full Text] [Related]
9. YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection. Schiavon LL; Carvalho-Filho RJ; Narciso-Schiavon JL; Medina-Pestana JO; Lanzoni VP; Ferraz ML; Silva AE Scand J Gastroenterol; 2010 May; 45(5):615-22. PubMed ID: 20163287 [TBL] [Abstract][Full Text] [Related]
10. Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort: the Boston children's hospital experience. Lee CK; Perez-Atayde AR; Mitchell PD; Raza R; Afdhal NH; Jonas MM J Pediatr; 2013 Oct; 163(4):1058-64.e2. PubMed ID: 23759423 [TBL] [Abstract][Full Text] [Related]
11. Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laborarory parameters. Matsumoto T; Tsurumoto T Clin Exp Rheumatol; 2001; 19(6):655-60. PubMed ID: 11791636 [TBL] [Abstract][Full Text] [Related]
12. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Parés A; Deulofeu R; Giménez A; Caballería L; Bruguera M; Caballería J; Ballesta AM; Rodés J Hepatology; 1996 Dec; 24(6):1399-403. PubMed ID: 8938169 [TBL] [Abstract][Full Text] [Related]
13. Analysis of chondrex (YKL-40, HC gp-39) in the cerebrospinal fluid of patients with spine disease. Tsuji T; Matsuyama Y; Natsume N; Hasegawa Y; Kondo S; Kawakami H; Yoshihara H; Iwata H Spine (Phila Pa 1976); 2002 Apr; 27(7):732-5. PubMed ID: 11923666 [TBL] [Abstract][Full Text] [Related]
14. A chitinase-like protein in the lung and circulation of patients with severe asthma. Chupp GL; Lee CG; Jarjour N; Shim YM; Holm CT; He S; Dziura JD; Reed J; Coyle AJ; Kiener P; Cullen M; Grandsaigne M; Dombret MC; Aubier M; Pretolani M; Elias JA N Engl J Med; 2007 Nov; 357(20):2016-27. PubMed ID: 18003958 [TBL] [Abstract][Full Text] [Related]
15. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. Berres ML; Papen S; Pauels K; Schmitz P; Zaldivar MM; Hellerbrand C; Mueller T; Berg T; Weiskirchen R; Trautwein C; Wasmuth HE J Hepatol; 2009 Feb; 50(2):370-6. PubMed ID: 19070929 [TBL] [Abstract][Full Text] [Related]
16. Non invasive prediction of severe fibrosis in patients with alcoholic liver disease. Tran A; Hastier P; Barjoan EM; Demuth N; Pradier C; Saint-Paul MC; Guzman-Granier E; Chevallier P; Tran C; Longo F; Schneider S; Piche T; Hebuterne X; Benzaken S; Rampal P Gastroenterol Clin Biol; 2000; 24(6-7):626-30. PubMed ID: 10962384 [TBL] [Abstract][Full Text] [Related]
17. Serum level of YKL-40 does not predict advanced liver fibrosis in children with chronic hepatitis B. Lebensztejn DM; Skiba E; Werpachowska I; Sobaniec-Łotowska ME; Kaczmarski M Adv Med Sci; 2007; 52():120-4. PubMed ID: 18217402 [TBL] [Abstract][Full Text] [Related]
18. Serum fibrosis markers can predict rapid fibrosis progression after liver transplantation for hepatitis C. Pungpapong S; Nunes DP; Krishna M; Nakhleh R; Chambers K; Ghabril M; Dickson RC; Hughes CB; Steers J; Nguyen JH; Keaveny AP Liver Transpl; 2008 Sep; 14(9):1294-302. PubMed ID: 18756457 [TBL] [Abstract][Full Text] [Related]
19. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement. Nordenbaek C; Johansen JS; Halberg P; Wiik A; Garbarsch C; Ullman S; Price PA; Jacobsen S Scand J Rheumatol; 2005; 34(4):293-7. PubMed ID: 16195162 [TBL] [Abstract][Full Text] [Related]
20. Serum YKL-40 predicts adverse clinical outcomes in patients with chronic heart failure. Bilim O; Takeishi Y; Kitahara T; Ishino M; Sasaki T; Suzuki S; Shishido T; Kubota I J Card Fail; 2010 Nov; 16(11):873-9. PubMed ID: 21055651 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]